Precision Medicine Group (PMG), a specialised services company that supports next generation approaches to drug development and commercialisation, announced on Thursday that it has acquired Project Farma, a patient-focused bioengineering services company that supports life science innovators in the manufacturing and scale-up of advanced therapies.
This transaction is intended to add Project Farma's expertise to Precision's suite of end-to-end cell and gene therapy capabilities to help development and commercialisation.
Project Farma is headed by executive leaders Anshul Mangal, John Khoury and Tony Khoury. It has led over a dozen manufacturing facility builds with capital investments of more than USD1bn. It will be part of Precision for Medicine, PMG's research and development services unit.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA